As maraviroc significantly inhibited CCL5-induced GSC invasion (Figure 6), we propose targeting CCL5/CCR5 signaling as novel glioblastoma therapeutics, as initially suggested by Kast et al. [60]. The gene discussed is CCL5; the disease is glioblastoma.